Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The nature of evidence in aging research

Posted on June 5th, 2017 by in Pharma R&D

It seems a while since there was focus on aging as a suitable target for pharmaceutical intervention. The days of Sirtuins and red wine may be long gone, but the scope of the opportunity to support healthy aging is becoming more relevant. It was therefore with some interest that I noticed several recent articles in FierceBiotech.

Continue reading “The nature of evidence in aging research” »

Assessing the State of the Genomic Revolution

Posted on May 29th, 2017 by in Pharma R&D

A few weeks ago, a number of experts in the field of genomics gathered in downtown Manhattan for Sequencing the Genome: Examining Modern Medicine, an event hosted by The Atlantic magazine. Continue reading “Assessing the State of the Genomic Revolution” »

Personalized vs. Precision Medicine

Posted on February 3rd, 2017 by in Pharma R&D

Last year was a year of impetus for precision medicine. Former President Obama’s budget for the 2016 fiscal year included $215 million for the National Institutes of Health (NIH), Continue reading “Personalized vs. Precision Medicine” »

The Success of Personalized Anti-Cancer Therapies

Posted on January 4th, 2017 by in Pharma R&D

Every day, thousands of cancer patients face difficult choices about their treatment options. For those affected by advanced, stage 4 cancer, the decisions can be particularly painful. Continue reading “The Success of Personalized Anti-Cancer Therapies” »

  1. 1
  2. 2